Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

News Conference News ESC 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

Caitlin E. Cox

August 31, 2021

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Yael L. Maxwell

September 04, 2019

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

Todd Neale

August 26, 2018

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Shelley Wood

August 26, 2018

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

Presentation ESC 2012

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Presenter: Willem Dewilde

August 28, 2012

News Conference News ESC 2012

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Yael L. Maxwell

August 28, 2012

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

Advertisement

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Long-term Antiplatelet Therapy: All Risk, No Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content